Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 9/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15237484 | 0.83 | SSTR4 (0.38) | SSTR4SMN1; SMN2TP53HIF1A | |
| SCHEMBL24174035 | 0.83 | SSTR4 (0.43) | SSTR4SMN1; SMN2TP53HIF1ANPC1 | |
| SCHEMBL24663489 | 0.81 | SMN1; SMN2 (0.56) | SSTR4SMN1; SMN2TP53HIF1AL3MBTL1 | |
| SCHEMBL13209721 | 0.79 | HTT (0.47) | L3MBTL1 | |
| SCHEMBL13209751 | 0.78 | SSTR4 (0.38) | SSTR4SMN1; SMN2TP53 | |
| SCHEMBL2442815 | 0.73 | KDM4C (0.42) | SSTR4SMN1; SMN2TP53HIF1ANPC1 | |
| SCHEMBL5511858 | 0.73 | SSTR4 (0.39) | SSTR4SMN1; SMN2TP53CES2CES1 | |
| SCHEMBL13576849 | 0.73 | GRM4 (0.42) | SSTR4SMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL19570353 | 0.72 | SSTR4 (0.65) | SSTR4 | |
| SCHEMBL3434886 | 0.72 | HIF1A (0.61) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040706-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040706-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-1836201-B1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH INC (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | SSTR4 4060/4885SMN1; SMN2 2913/4885TP53 27/4885 |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | SSTR4 4060/4885SMN1; SMN2 2913/4885TP53 27/4885 |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | SSTR4 4060/4885SMN1; SMN2 2913/4885TP53 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.